Literature DB >> 10888311

Pharmacokinetic variability and therapeutic drug monitoring actions at steady state.

M Ramanathan1.   

Abstract

PURPOSE: To develop a mathematical model for therapeutic drug monitoring and to assess the kinetic relationships between the intensity of corrective action and the approach of drug concentrations to target values.
METHODS: A mathematical model that succinctly accounts for the corrective actions and the variability inherent in the pharmacokinetics was used.
RESULTS: The validity of the variability term was tested using experimental data for steady state concentrations of the drug procainamide. The approach of the monitored process to the target value followed exponential kinetics and an analytical expression for dependence the variance with time and various dosing parameters was derived. The variance of the drug concentration depends critically on a single non-dimensional parameter containing the rate constant for the therapeutic corrective actions and a coefficient describing the variance rate. When the rate constant for the therapeutic corrective actions was less than this critical value, the variance increased indefinitely.
CONCLUSIONS: From a dosing standpoint, large variances in drug concentrations are undesirable because some patients will be overdosed or underdosed. Since deterministic models cannot provide analytical solutions for the moments of drug concentration distribution functions, stochastic models can be used to provide useful insights into the design of therapeutic regimens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888311     DOI: 10.1023/a:1007573001055

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  7 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

2.  A method for estimating pharmacokinetic risks of concentration-dependent drug interactions from preclinical data.

Authors:  M Ramanathan
Journal:  Drug Metab Dispos       Date:  1999-12       Impact factor: 3.922

3.  Impact of pharmacodynamic variability on drug delivery(1).

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-09-07       Impact factor: 15.470

4.  Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring.

Authors:  Y Merlé; F Mentré
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

5.  An application of Ito's lemma in population pharmacokinetics and pharmacodynamics.

Authors:  M Ramanathan
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

6.  Serum procainamide levels as therapeutic guides.

Authors:  J Koch-Weser
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

7.  Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography.

Authors:  L Yuh; S Beal; M Davidian; F Harrison; A Hester; K Kowalski; E Vonesh; R Wolfinger
Journal:  Biometrics       Date:  1994-06       Impact factor: 2.571

  7 in total
  2 in total

1.  Grey-box pharmacokinetic/pharmacodynamic modelling of a euglycaemic clamp study.

Authors:  Christoffer Wenzel Tornøe; Judith L Jacobsen; Henrik Madsen
Journal:  J Math Biol       Date:  2003-12-02       Impact factor: 2.259

2.  A stochastic version of corticosteriod pharmacogenomic model.

Authors:  Xiaohong Qi
Journal:  AAPS J       Date:  2005-06-23       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.